Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007

Cancer

Volumn 120, Issue 8, 2014, Pages 1162-1170

  Haynes, Alex B ^a   You, Y Nancy ^a   Hu, Chung Yuan ^a   Eng, Cathy ^a   Kopetz, E Scott ^a   Rodriguez Bigas, Miguel A ^a   Skibber, John M ^a   Cantor, Scott B ^a   Chang, George J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

rectal cancer, neoadjuvant therapy, adjuvant therapy, chemotherapy, Surveillance, Epidemiology, and End Results (SEER); SEER Medicare

Indexed keywords

FLUOROURACIL; OXALIPLATIN;

ADJUVANT CHEMORADIOTHERAPY; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CARCINOMA; RETROSPECTIVE STUDY; TREATMENT OUTCOME; VERY ELDERLY;

RECTAL CANCER, NEOADJUVANT THERAPY, ADJUVANT THERAPY, CHEMOTHERAPY, SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER); SEER-MEDICARE;

AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; COHORT STUDIES; FEMALE; HUMANS; MALE; MEDICARE; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; RETROSPECTIVE STUDIES; SEER PROGRAM; TIME FACTORS; UNITED STATES;

EID: 84898032442     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28545     Document Type: Article

References (31)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB,. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from Surveillance, Epidemiology, and End Results-Medicare. J Clin Oncol. 2001; 19: 3712-3718.
3. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351: 1731-1740.
4. Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355: 1114-1123.
5. Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012; 30: 1770-1776.
6. Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010; 11: 835-844.
7. Jacob S, Ng W, Asghari R, Delaney GP, Barton MB,. Chemotherapy in rectal cancer: variation in utilization and development of an evidence-based benchmark rate of optimal chemotherapy utilization. Clin Colorectal Cancer. 2011; 10: 102-107.
8. Khrizman P, Niland JC, ter Veer A, et al. Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a National Comprehensive Cancer Network analysis. J Clin Oncol. 2013; 31: 30-38.
9. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
10. Le H, Ziogas, A, Lipkin, SM, Zell, JA,. Effects of socioeconomic status and treatment disparities in colorectal cancer survival. Cancer Epidemiol Biomarkers Prevent. 2008; 17: 1950-1962.
11. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF,. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol. 2002; 20: 1192-1202.
12. Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003; 21: 1293-1300.
13. Govindarajan R, Shah RV, Erkman LG, Hutchins LF,. Racial differences in the outcome of patients with colorectal carcinoma. Cancer. 2003; 97: 493-498.
14. Horner MJ, Ries LAG, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2006. Bethesda, MD: National Cancer Institute; 2009. Available at: http://seer.cancer.gov/csr/1975-2006/, based on November 2008 SEER data submission, posted to the SEER web site, 2009.
15. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG,. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993; 31: 732-748.
16. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF,. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40 (8 suppl): IV-3-IV-18.
17. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007; 370: 2020-2029.
18. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25: 2198-2204.
19. Park ES, Rabinovsky R, Carey M, et al. Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell line set. Mol Cancer Ther. 2010; 9: 257-267.
20. Charlson ME, Pompei P, Ales KL, MacKenzie CR,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
21. Romano PS, Roos LL, Jollis JG,. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993; 46: 1075-1079; discussion 1081-1090.
22. Collette L, Bosset JF, den Dulk M, et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol. 2007; 25: 4379-4386.
23. Merkow RP, Bentrem DJ, Chow WB, Cohen ME, Ko CY, Bilimoria KY,. Effect of postoperative complications on adjuvant chemotherapy use in stage III colon cancer [abstract]. J Clin Oncol. 2012; 30 (suppl 4). Abstract 551.
24. Fernandez-Martos C, Pericay C, Aparicio J, et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cancer de Recto 3 study. J Clin Oncol. 2010; 28: 859-865.
25. Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012; 13: 679-687.
26. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001; 345: 1091-1097.
27. Wildes TM, Kallogjeri D, Powers B, et al. The benefit of adjuvant chemotherapy in elderly patients with stage III colorectal cancer is independent of age and comorbidity. J Geriatr Oncol. 2010; 1: 48-56.
28. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006; 24: 4085-4091.
29. Jessup JM, Stewart A, Greene FL, Minsky BD,. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA. 2005; 294: 2703-2711.
30. Schrag D, Cramer LD, Bach PB, Begg CB,. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001; 93: 850-867.
31. Sanoff HK, Carpenter WR, Sturmer T, et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol. 2012; 30: 2624-2634.